

Managing Frequently Relapsing Childhood Nephrotic Syndrome: A Novel Combination of Synacthen and Mycophenolate Mofetil

Aamir Jalal Al-Mosawi

Advisor doctor and expert trainer, The National Center of Training and Development and Baghdad Medical City, Baghdad, Iraq.

Corresponding Author: Aamir Jalal Al-Mosawi, Advisor doctor and expert trainer, The National Center of Training and Development and Baghdad Medical City, Baghdad, Iraq.

Received Date: 08 November 2024 | **Accepted Date:** 15 November 2024 | **Published Date:** 22 November 2024

Citation: Aamir Jalal Al-Mosawi, (2024), Managing Frequently Relapsing Childhood Nephrotic Syndrome: A Novel Combination of Synacthen and Mycophenolate Mofetil, *Clinical Medical Reviews and Reports*; 6(10):

DOI: [10.31579/2690-8794/243](https://doi.org/10.31579/2690-8794/243)

Copyright: © 2024 Aamir Jalal Al-Mosawi, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Childhood nephrotic syndrome is a prevalent renal disorder characterized by generalized edema due to hypoalbuminemia from heavy proteinuria. This syndrome can be classified as primary or secondary, with the majority of cases being primary. Historical perspectives on nephrotic syndrome illustrate significant advancements in understanding its pathology and treatment, beginning with early descriptions in the 15th century and evolving through the introduction of terms like "nephrosis."

Current management primarily relies on corticosteroids, but issues such as frequent relapses and steroid dependency necessitate alternative therapies. Recent approaches include the use of levamisole and mycophenolate mofetil, alongside the resurgence of intramuscular ACTH (synacthen) as a treatment option.

This article presents a case study of a boy with frequently relapsing steroid-dependent nephrotic syndrome, successfully treated with a novel combination of intramuscular synacthen and mycophenolate mofetil.

This regimen effectively reduced the required dosage of steroids while minimizing associated adverse effects, particularly psychiatric symptoms. The findings underscore the potential for innovative therapeutic strategies in managing challenging cases of childhood nephrotic syndrome.

Keywords: Frequently relapsing nephrotic syndrome; challenging cases; innovative therapeutic strategies

Introduction

Childhood nephrotic syndrome is primarily characterized by generalized edema due to hypoalbuminemia from significant proteinuria. Most cases are primary, with historical descriptions dating back to the 15th century. Key advancements in understanding and treating the syndrome include the introduction of terms like "nephrosis" by Friedrich von Müller and the distinction between inflammatory and non-inflammatory renal diseases by Franz Volhard and Theodor Fahr [1-18].

In 1484, Cornelus Roelans from Belgium likely described one of the first cases of nephrotic syndrome, noting whole-body swelling in a child [1]. In 1722, Theodore Zwinger from Basel provided a detailed account of childhood nephrotic syndrome, highlighting reduced urine output and attributing this to obstruction of the renal tubules [2].

In 1827, Richard Bright (Figure 1A) suggested that generalized edema combined with proteinuria is indicative of renal disease [3].



Figure-1A: Richard Bright (September 28, 1789-December 16, 1858) was an English physician

John Bostock (Figure 1B) observed a correlation between high urinary protein excretion and low serum protein levels [4].



Figure-1B: John Bostock, Jr. (June 29, 1773-August 6, 1846), an English physician and scientist

In 1846, George Johnson (Figure 1C) posited that the renal disease identified by Bright was a localized manifestation of a broader constitutional disorder. He also noted that not all cases of Richard Bright included albuminuria, which represents what Rayser called “Albuminous nephritis”, hinting at the heterogeneous nature of Bright's disease [5].




Figure-1C: George Johnson (November, 29 1818-June, 3 1896) was an English physician

In 1905, Friedrich von Müller (Figure 1D) introduced the term “nephrosis” to describe the histological changes in renal tubules which were thought to be degenerative, distinguishing these non-inflammatory disorders from “parenchymatous

nephritis” which suggests an exudative and inflammatory disorder. Later, nephrosis has been used to describe the clinical condition which has been increasingly known nephrotic syndrome [6].




Figure-1D: Friedrich von Müller (September 17, 1858-November 18, 1941), a German physician

In 1914, Franz Volhard (Figure 1E) and Theodor Fahr (Figure 1F) reaffirmed the distinction between nephroses, a non-inflammatory disease and inflammatory nephritides in their classification of renal disorders [7].



Figure-1E: Franz Volhard (May 2, 1872-May 24, 1950), a German physician



Figure-1F: Karl Theodor Fahr (October 3, 1877-October 29, 1945), a German pathologist

Childhood nephrotic syndrome is primarily steroid-responsive, often characterized by frequent relapses and steroid dependence. Various steroids and synthetic adrenocorticotropic hormone (ACTH) analogs have been utilized since the 1950s [8-16].

Henry Lewis Barnett (Figure 1G) and his team were among the first to explore ACTH and cortisone treatment for nephrotic syndrome in 1950 [8].



Figure-1G: Henry Lewis Barnett (1914-2001), An American pioneer of pediatric nephrology

Gavin Arneil and Wilson reported the effective use of cortisone in 1952 and detailed treatment outcomes for 16 patients in 1953, emphasizing its role in inducing diuresis [10, 11].

By 1954, Lauson et al. noted the positive impact of ACTH on glomerular permeability in childhood nephrotic syndrome.

Gavin Arneil (Figure 1H) was likely the first to report the use of prednisolone for treating nephrotic syndrome in 1956 [13].



Figure-1H: Gavin Cranston Arneil (March 7, 1923-January 21, 2018), a Scottish pioneer of pediatric nephrologist from Glasgow

In 1968, John Stewart Cameron (Figure 1I) demonstrated that the minimal change lesion, the predominant histopathological type in childhood nephrotic syndrome, is the only type that consistently responds to corticosteroid treatment within eight weeks [17].



Figure-1I: John Stewart Cameron (July 5, 1934-July 30, 2023), a British nephrologist

Chlorambucil and cyclophosphamide began to be used in the 1970s for challenging cases with significant steroid side effects [19-24].

The 1979 international study of kidney disease involved 54 children with frequently relapsing nephrotic syndrome, revealing that both treatment regimens were inadequate in preventing relapses [25].

Treatment strategies have evolved over the decades, with steroids being the primary therapy. However, issues such as frequent relapses and steroid dependency have led to the exploration of alternative treatments like levamisole and mycophenolate mofetil. Notably, intramuscular ACTH (synacthen) has gained attention for its beneficial effects on glomerular permeability and potential to alleviate psychiatric side effects associated with high-dose steroids.

In 1980, Tanphaichitr et al. highlighted the potential role of T-cell lymphocyte dysfunction in minimal change nephrotic syndrome, employing levamisole, an anthelmintic having immune stimulant property to treat seven children with minimal change nephrotic syndrome during relapses with positive outcomes.

Levamisole was used in a dose of 1.5 to 3.9 mg/kg biweekly for one to six months. After Treatment was associated with a complete remission without the occurrence of side effects [26].

In 1984, Patrick Niaudet (Figure 1J) from Paris and his research team reported successful levamisole treatment in children with frequently relapsing nephrotic syndrome, leading to reduced corticosteroid doses without significant side effects [27].



Figure-1J: Patrick Niaudet, a pediatric nephrologist from France

They described the treatment of 30 cases of childhood frequently relapsing nephrotic syndrome with levamisole (2.5 mg/kg twice weekly) for a mean period of 9.9 months. Treatment in sixteen patients enabled marked reduction of

corticosteroids without experiencing a relapse. However, levamisole was not effective in 14 patients. Seven patients who responded to levamisole therapy, experienced reduction of neutrophils to below $4 \times 10^9/L$. Three patients experienced transient granulocytopenia.

Therefore, Niaudet and his research team suggested that levamisole can be useful option in frequently relapsing nephrotic syndrome, and with minimal side effects [27].

The British Association for Pediatric Nephrology supported levamisole, an immunostimulant agent as an alternative therapy in 1991, confirming its effectiveness in maintaining steroid-free remission.

They reported the treatment of 31 cases of frequently relapsing and dependent steroid nephrotic syndrome with levamisole (2.5 mg/kg on alternate days), while 30 patients received placebo for a maximum of 112 days. In both groups, prednisolone was progressively decreased and was discontinued by 56 days. 14 patients who received levamisole and only four patients who received placebo remained in remission at 112 days (log rank analysis p less than 0.01). The British Association for Pediatric Nephrology considered levamisole to be effective in maintaining a steroid-free remission, and it was not associated with important side effects [28].

Capodicasa et al. in 1986 and Brodehl in 1991 emphasized the possible occurrence of nephrotoxicity during the use of cyclosporine in the treatment of frequently relapsing nephrotic syndrome as evidenced by serum creatinine monitoring [29, 30].

Concerns regarding nephrotoxicity with cyclosporine prompted increased recommendations for levamisole in difficult cases of primary childhood nephrotic syndrome [31-39].

In 1998, Briggs from the United States suggested mycophenolate mofetil as a beneficial steroid-sparing agent for challenging cases of nephrotic syndrome. Mycophenolate mofetil can be used instead of cyclosporine in difficult cases of childhood nephrotic syndrome caused by minimal change disease and possibly by other glomerular disease [40].

Patients and methods

We utilized existing evidence to enhance the management of challenging childhood conditions such as frequently relapsing, steroid-dependent, and steroid-resistant nephrotic syndrome. We previously treated a boy (Figure 2A) with frequently relapsing steroid nephrotic syndrome who faced significant steroid toxicity, resulting in stunted growth due to prolonged high doses of prednisolone (2 mg/kg daily). His treatment involved an alternate-day regimen of levamisole combined with mycophenolate mofetil, significantly reducing the prednisolone dosage and its adverse effects.

This paper describes the use of a new therapeutic approach in the treatment of a second boy who had frequently relapsing nephrotic syndrome that didn't respond to cyclosporine.



Figure 2A: A boy with frequently relapsing steroid nephrotic syndrome who faced significant steroid toxicity, resulting in stunted growth

Results

The boy first presented with nephrotic syndrome on August 20, 2020, at approximately seven years of age. By July 20, 2024, he was experiencing his seventh or eighth episode and was on oral prednisolone (10 mg daily) and cyclosporine (100 mg daily). His previous relapses had required high-dose prednisone, diuretics, and, at times, intravenous albumin.

Cyclosporine treatment was started before about 14 months. Previous relapses were treated with large dose oral prednisone and diuretics, and sometime he was receiving intravenous infusion of albumin.

His father noted that the use of high-dose prednisone during relapses correlated with depressive symptoms that did not fully resolve with dose reductions.

On July 20, 2024, lab tests revealed normal renal function: serum creatinine at 0.4 mg/dL and blood urea at 25.5 mg/dL, with total serum protein at 4.2 g/dL and serum albumin at 1.5 g/dL. Urine analysis showed 200 mg/dL albumin (normal levels are <2 mg/dL).

The patient was not treated with the traditional large daily dose of prednisone, but he was treated with low-dose prednisolone, intramuscular synacthen (Tetracosactide, 1 mg weekly [Tetracosactride, a synthetic peptide with an amino acid sequence identical to the first 24 amino acids of corticotrophin]), and mycophenolate mofetil, starting at 1000 mg in two divided doses and increasing to 1500 mg daily after one week when urine showed 100 mg/dL albumin.

Prior to starting mycophenolate, complete blood studies indicated normal levels: Hemoglobin at 14.2 g/dL, WBC at $7.2 \times 10^9/L$, lymphocytes at $3.7 \times 10^9/L$ (47.2%), and platelets at $352 \times 10^9/L$.

By August 3, 2024, blood tests showed Hemoglobin at 13.4 g/dL, WBC at $7.9 \times 10^9/L$, lymphocytes at $3.6 \times 10^9/L$ (44.0%), and platelets at $332 \times 10^9/L$.

On August 17, 2024, the boy has received 5 intramuscular synacthen urine exam showed only trace amount of albumin. Intramuscular synacthen was stopped. Total serum protein was 7.0 g / dL and serum albumin was 4.2 g / d. Figure 2B illustrates the boy on October 12, 2024, with urine tests showing no detectable albumin.



Figure 2B: The boy on October 12, 2024, with urine tests showing no detectable albumin

Discussion

The beneficial effects of ACTH on glomerular permeability in childhood nephrotic syndrome were first reported in 1954 by Lauson et al. Subsequent studies (2004, 2010) indicated that ACTH could improve various nephritic syndromes by protecting podocytes from damage [42-47].

In 2004, Berg and Arnadottir reported that ACTH therapy was associated with improvement in a variety nephritic syndrome [42].

In 2010, the work of Gong and Dworkin suggested that ACTH has a protective effect on podocytes as it can reduce foot-process effacement, podocyte apoptosis, and decrease the decline in glomerular expression of podocyte markers, including nephrin, vimentin, and podocin. Therefore it can have a beneficial effect when used in different types of glomerular disorders [44].

In 2011, Rujun Gong from the United States emphasized the renaissance of corticotropin treatment in nephrotic nephropathies [45].

Chlorambucil and cyclophosphamide and have used as early as the 1970s in difficult cases associated with significant steroid side effects [19-24].

In 1979, Wiggelinkhuizen and colleagues reported the treatment of thirteen childhood cases of frequently relapsing nephrotic syndrome with chlorambucil (Leukeran), a cytotoxic drug in a dose of 0.2 mg/kg/day for eight weeks. Treatment was associated with remission in 11 patients for an average of 31 months. No side-effects of therapy were observed in this study, but several grave complications of high-dosage therapy have been reported in the recent literature [23].

In 1980, Williams et al. reported the treatment of 59 childhood cases of frequently relapsing, steroid dependent and resistant idiopathic nephrotic syndrome with chlorambucil and prednisone for 5 to 15 weeks. 95% of the patients experienced remission at one year and 85% at 4 years. All patients except two experienced remissions lasting longer than steroid-induced remissions. Only eight other patients experienced one or more relapses after treatment [24].

The boy in this report was experiencing steroid-induced behavioral and psychiatric abnormalities mostly in the form of depressive mood.

In 2013, Youssef et al from Egypt reported a study which included thirty children with steroid sensitive nephrotic syndrome who were at remission or were receiving prednisolone in a low dose and experienced relapse. The study showed that prednisolone treatment in high doses was associated psychiatric abnormalities including anxiety and depression [41].

Several studies supported the potential of intramuscular synacthen to have a beneficial effect in childhood nephrotic syndrome [42-47].

Our current study highlights intramuscular synacthen's role in mitigating the psychiatric symptoms associated with high doses of prednisolone.

In 1896, Bartolomeo Gosio (Figure-3) reported the isolation of mycophenolic acid, an antibacterial from the mould *Penicillium brevicompactum*. The novel compound has an antibacterial property against anthrax bacterium. However, mycophenolic mofetil was not introduced into clinical use.

In 1912, Alsberg and O.M. Black from the United States also reported its isolation.

Mycophenolate mofetil, derived from mycophenolic acid, has been established as a safe and effective treatment for preventing immune rejection in organ transplants [48-50]. It has also shown promise in managing childhood nephrotic syndrome [52-67]

Mycophenolate mofetil (Cellcept), a derivative of mycophenolic acid, and its prodrug was introduced by Anthony Allison a geneticist from South African and his wife Elsie M Eugui during the early 1970s, and has been used as an antimetabolite immunosuppressive agent that work by inhibiting purine synthesis.

Mycophenolic mofetil has been considered safe and useful in preventing the immune rejection of allografts since the early 1990s. Therefore, it has been increasingly used as an anti-rejection agent in organ transplants [48-50].



Figure-3: Bartolomeo Gosio (17 March 17, 1863-April 13, 1944), an Italian medical scientist

In 1996, Confavreux and Moreau from France emphasized the available evidence suggesting that mycophenolate mofetil has a good safety profile and lacks mutagenic effect and chromosome breakage [51].

During the previous decades, mycophenolate mofetil has been used extensively with a beneficial effect in childhood nephrotic syndrome [52-68].

In our case, the combination of intramuscular synacthen and oral mycophenolate resulted in successful treatment without significant side effects, effectively minimizing steroid toxicity, particularly concerning psychiatric manifestations.

Conclusion

Childhood nephrotic syndrome remains a complex condition requiring a multifaceted approach to management, particularly in cases that are frequently relapsing or steroid-dependent. The historical evolution of understanding this disorder underscores the significance of ongoing research and innovation in treatment strategies.

The successful use of a combination therapy involving intramuscular synacthen and mycophenolate mofetil in the presented case demonstrates the potential for alternatives to traditional corticosteroid treatments. This approach not only alleviated the nephrotic syndrome symptoms but also mitigated the psychiatric side effects commonly associated with high-dose steroid therapy.

Future research should continue to explore and validate such therapeutic combinations to optimize outcomes for children with challenging nephrotic syndrome, aiming for effective management with minimal adverse effects.

Acknowledgement

The author has the copyrights of all the sketches (Figures) included in this paper.

Conflict of interest: None.

References

1. Roelans C. Liber de Aegritudinibus Infantium. München: Verl. der Mu`nchner Dr. (1484).
2. Zwinger T (1974). Anasarca puerorum. In: Basel E, Thurnis JR. editors. Paedioatreaia Pract Curationem Puerorumque Morborum Puerilium etc 1974; 5: 659-666.
3. Bright R. Reports of Medical Cases. London: Orme; (1827).
4. [Cameron JS \(1994\). John Bostock MD FRS \(1773-1846\): physician and chemist in the shadow of a genius. Am J Nephrol 1994; 14\(4-6\):365-70.](#)

5. [Johnson G \(1846\). On the minute anatomy and pathology of Bright's disease of the kidney, and on the relation of the renal disease to those diseases of the liver, heart, and arteries, with which it is commonly associated. *Med Chir Trans* 1846; 29:1-24.](#)
6. Müller F (1905). Morbus Brightii. *Verh Dtsch Ges Path* 1905; 9:64-99.
7. Volhard , Fahr T (1914). Die Brightsche Nieren krankheit Berlin. *Springer Verlag* 1914.
8. [Barnett HL, McNamara H, McCrory W, Forman C, Rapoport M, Michie A, Barbero G \(1950\). The effects of ACTH and cortisone on the nephrotic syndrome. *AMA Am J Dis Child Sep*; 80\(3\):519-20.](#)
9. [Rapoport M, McCrory WW, Michie AJ, Barbero G, Barnett HL,et.al \(1951\). Effects of corticotrophin on children with nephrotic syndrome: clinical observations on 34 children; the effect of cortisone in 4. *AMA Am J Dis Child* 1951 Aug; 82\(2\):248-53.](#)
10. [Arneil GC, Wilson HE \(1952\). Cortisone treatment of nephrosis. *Arch Dis Child* 1952 Aug; 27\(134\):322-8.](#)
11. [Arneil GC, Wilson HE \(1953\). A.C.T.H. in nephrosis. *Arch Dis Child* 1953 Oct; 28\(141\):372-80. 0](#)
12. [Lauson HD, Forman CW, McNamara H, Mattar G, Barnett HL \(1954\). The effect of corticotropin \(ACTH\) on glomerular permeability to albumin in children with the nephrotic syndrome. *J Clin Invest* 1954; 33: 657-664.](#)
13. [Arneil GC \(1956\). Treatment of nephrosis with prednisolone. *Lancet* 1956 Apr 14; 270 \(6920\): 409-11.](#)
14. Prieto MM, Senet RE (1957). Seis casos de nefrosis lipídica tratados con prednisolona [6 Cases of lipoid nephrosis treated with prednisolone]. *Dia Med* 1957 Dec 2; 29(87):3230-2.
15. [Holland WW, Colley JR, Moore KA \(1958\). The nephrotic syndrome in children treated with a course of prednisolone. *Br Med J* 1958 Aug 23; 2\(5094\):479-81.](#)
16. Fontan (1959). [Evaluation of corticotherapy in pediatric medicine]. *J Med Bord* 1959 Dec; 136: 1400-2 [Article in French].
17. [Cameron JS \(1968\). Histology, protein clearances, and response to treatment in the nephrotic syndrome. *Br Med J* 1968 Nov 9; 4\(5627\):352-6.](#)
18. [Habib R, Kleinknecht C \(1971\). The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases. *Pathol Annu* 1971; 6:417-74.](#)
19. [Grupe WE, Makker SP, Ingelfinger JR \(1976\). Chlorambucil treatment of frequently relapsing nephrotic syndrome. *N Engl J Med* 1976 Sep 30; 295\(14\):746-9.](#)
20. Martini RJ, Gomila A, Solanas G (1977). Estudio longitudinal en niños con síndrome nefrótico y lesión glomerular mínima [Longitudinal study in children with the nephrotic syndrome and minimal glomerular lesion]. *Bol Med Hosp Infant Mex* 1977 Sep-Oct; 34(5):1105-16 [Article in Spanish].
21. [Baluarte HJ, Hiner L, Gruskin AB \(1978\). Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial. *J Pediatr* 1978 Feb; 92\(2\):295-8.](#)
22. [Guesry P, Lenoir G, Broyer M \(1978\). Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. *J Pediatr* 1978 Feb; 92\(2\):299-303.](#)
23. [Wiggelinkhuizen J, McDonald R, van Dugteren GR \(1979\). Chlorambucil therapy in childhood nephrotic syndrome. *S Afr Med J* 1979 Jun 9; 55\(24\):971-5.](#)
24. [Williams SA, Makker SP, Ingelfinger JR, Grupe WE \(1980\). Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. *N Engl J Med* 1980 Apr 24; 302\(17\):929-33.](#)
25. The international study of kidney disease. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. *J Pediatr*. 1979 Aug; 95(2):239-43.
26. [Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S \(1980\). Treatment of nephrotic syndrome with levamisole. *J Pediatr* 1980 Mar; 96\(3 Pt 1\):490-3.](#)
27. [Niaudet P, Drachman R, Gagnadoux MF, Broyer M \(1984\). Treatment of idiopathic nephrotic syndrome with levamisole. *Acta Paediatr Scand* 1984 Sep; 73\(5\):637-41.](#)
28. [British Association for Paediatric Nephrology. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. *Lancet*. 1991 Jun 29; 337\(8757\):1555-7.](#)
29. [Capodicasa G, De Santo NG, Nuzzi F, Giordano C \(1986\). Cyclosporin A in nephrotic syndrome of childhood: A 14 month experience. *Int J Pediatr Nephrol* 1986 Apr-Jun; 7\(2\):69-72.](#)
30. [Brodehl J \(1991\). The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies. *Eur J Pediatr* 1991 Apr; 150\(6\):380-7.](#)
31. [Dayal U, Dayal AK, Shastry JC, Raghupathy P \(1994\). Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. *Nephron* 1994; 66\(4\):408-12.](#)
32. [Tenbrock K, Müller-Berghaus J, Fuchshuber A, Michalk D, Querfeld U \(1998\). Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome. *Pediatr Nephrol* 1998 Aug; 12\(6\):459-62.](#)
33. [Fu LS, Shien CY, Chi CS \(2004\). Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. *Nephron Clin Pract*. 2004; 97\(4\):c137-41.](#)
34. [Donia AF, Ammar HM, El-Agroudy Ael-B, Moustafa Fel-H, Sobh MA \(2005\). Long-term results of two unconventional agents in steroid-dependent nephrotic children. *Pediatr Nephrol* 2005 Oct; 20\(10\):1420-5.](#)

35. [Hafeez F, Ahmed TM, Samina U \(2006\). Levamisole in steroid dependent and frequently relapsing nephrotic syndrome. *J Coll Physicians Surg Pak* 2006 Jan; 16\(1\):35-7.](#)
36. [Abeyagunawardena AS, Karunadasa U, Jayaweera H, Thalagahagoda S, Tennakoon S, Abeyagunawardena S \(2017\). Efficacy of higher-dose levamisole in maintaining remission in steroid-dependant nephrotic syndrome. *Pediatr Nephrol* 2017 Aug; 32\(8\):1363-1367.](#)
37. [Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, et.al \(2018\); all members of the Levamisole Study Group. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. *Kidney Int.* 2018 Feb; 93\(2\):510-518.](#)
38. [Bhatt GC, Patel B, Das RR, Malik S, Bitzan M, et.al \(2023\). Efficacy and safety of levamisole in childhood nephrotic syndrome: A meta-analysis. *Indian J Pharmacol* 2023 Jan-Feb; 55\(1\):43-52.](#)
39. [Sinha A, Devi KG, Kalra S, Mani K, Hari P, Bagga A \(2024\). An open label non-inferiority randomized controlled trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome. *Kidney Int* 2024 May; 105\(5\):1113-1123.](#)
40. [Briggs WA, Choi MJ, Scheel PJ Jr \(1998\). Successful mycophenolate mofetil treatment of glomerular disease. *Am J Kidney Dis.* 1998 Feb; 31\(2\):213-7.](#)
41. [Youssef DM, Abdelsalam MM, Abozeid AM, Youssef UM \(2013\). Assessment of behavior abnormalities of corticosteroids in children with nephrotic syndrome. *ISRN Psychiatry.* 2013 Apr 16; 2013:921253.](#)
42. [Berg AL, Arnadottir M \(2004\). ACTH-induced improvement in nephritic syndrome in patients with a variety of diagnoses. *Nephrol Dial Transplant* 2004; 19:1305-1307.](#)
43. [Afzal K, Bagga A, Menon S, Hari P, Jordan SC \(2007\). Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2007 Dec; 22\(12\):2059-65.](#)
44. [Gong R, Dworkin LD \(2010\). ACTH \(Acthar gel\) prevents proteinuria and renal injury in the remnant kidney: evidence for direct podocyte protection. *J Am Soc Nephrol* 2010; 21: 54-8A.](#)
45. [Gong R \(2011\). The renaissance of corticotropin therapy in proteinuric nephropathies. *Nat Rev Nephrol* 2011; 8:122-128.](#)
46. [Lorusso P, Bottai A, Mangione E, Innocenti M, Cupisti A, et.al \(2015\). Low-dose synthetic adrenocorticotrophic hormone-analog therapy for nephrotic patients: results from a single-center pilot study. *Int J Nephrol Renovasc Dis* 2015 Feb 5; 8:7-12.](#)
47. [Chakraborty R, Mehta A, Nair N, Nemer L, Jain R, Joshi H, Raina R \(2020\). ACTH treatment for management of nephrotic syndrome: A systematic review and reappraisal. *Int J Nephrol* 2020 Jun 4; 2020:2597079.](#)
48. [Florey HW, Gilliver K, Jennings MA, Sanders AG \(1946\). Mycophenolic Acid. An Antibiotic from *Penicillium brevicompactum* Dierckx. *The Lancet* 1946; 46-49.](#)
49. [Haydon GH, Hayes PC \(1994\). New immunosuppressive treatment in transplantation medicine. *Baillieres Clin Gastroenterol* 1994 Sep; 8\(3\):455-64.](#)
50. [Al-Mosawi AJ \(2023\). The Use of Mycophenolate Mofetil in Psoriasis: An Educational Article and Expert Opinion. *International Journal of Clinical Epidemiology* \(ISSN: 2835-9232\) May 2023; 2\(3\):1-4.](#)
51. [Confavreux C, Moreau T \(1996\). Emerging treatments in multiple sclerosis: azathioprine and mofetil. *Mult Scler* 1996 Jul; 1\(6\):379-84.](#)
52. [Chandra M, Susin M, Abitbol C \(2000\). Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. *Pediatr Nephrol* 2000 Mar; 14\(3\):224-6.](#)
53. [Zhao M, Chen X, Chen Y, Liu Z, Liu Y, et.al \(2001\). \[Mycophenolate mofetil in the treatment of primary nephrotic syndrome\]. *Zhonghua Yi Xue Za Zhi* 2001 May 10; 81\(9\):528-31 \[Article in Chinese\].](#)
54. [Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ \(2002\). Mycophenolate mofetil treatment for primary glomerular diseases. *Kidney Int.* 2002 Mar; 61\(3\):1098-114.](#)
55. [Mogvorósi A, Lippman HR, Feldman GM \(2002\). Successful treatment of steroid-resistant minimal change disease with mycophenolate mofetil. *Am J Nephrol* 2002 Sep-Dec; 22\(5-6\):569-72.](#)
56. [Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D \(2002\). Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. *Nephrol Dial Transplant* 2002 Nov; 17\(11\):2011-3.](#)
57. [Zhao M, Chen X, Chen Y, Liu Z, Liu Y, et.al \(2003\). Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. *Nephrology \(Carlton\).* 2003 Jun; 8\(3\):105-9.](#)
58. [Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB \(2003\). Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. *Pediatr Nephrol* 2003 Aug; 18\(8\):833-7.](#)
59. [Bagga A, Hari P, Moudgil A, Jordan SC \(2003\). Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. *Am J Kidney Dis* 2003 Dec; 42\(6\):1114-20.](#)
60. [Gellermann J, Querfeld U \(2004\). Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. *Pediatr Nephrol* 2004 Jan; 19\(1\):101-4.](#)
61. [Noroña B, Valentín M, Gutiérrez E, Praga M \(2004\). Tratamiento del síndrome nefrótico córtico-dependiente por lesiones mínimas con micofenolato mofetil \[Treatment of steroid-dependent minimal change-nephrotic syndrome with mycophenolate mofetil\]. *Nefrología* 2004; 24\(1\):79-82 \[Article in Spanish\].](#)

62. Kwinta-Rybicka J, Wilkosz K, Wierzchowska-Słowiacka EK, Ogarek I, Moczulska A, et al (2006). Mykofenolan mofetilu w leczeniu dzieci z zespołem nerczycowym: doniesienie wstępne [Mycophenolate mofetil in treatment of childhood nephrotic syndrome: Preliminary report]. *Przegl Lek* 2006; 63 Suppl 3:44-8 [Article in Polish].
63. [Tasanarong A, Thitiarchakul S \(2006\). Mycophenolate mofetil treatment in primary glomerular disease: one-year follow-up in steroid dependent and resistant nephrotic syndrome. *J Med Assoc Thai* 2006 Aug; 89 Suppl 2:S218-27.](#)
64. [Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N \(2006\). Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. *Clin J Am Soc Nephrol*. 2006 Nov; 1\(6\):1173-8.](#)
65. [Afzal K, Bagga A, Menon S, Hari P, Jordan SC \(2007\). Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2007 Dec; 22\(12\):2059-65.](#)
66. [Yi ZW, Dang XQ, He QN, Wu XC, Cao Y, et al \(2007\). Assessment of mycophenolate mofetil for treatment of frequently relapsing nephrotic syndrome in children. 2007 Dec; 32\(6\):938-40.](#)
67. [Yi ZW, Wu XC, Xu H, Zhou LJ, Wu YB, et al \(2008\). \[A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children\]. *Zhongguo Dang Dai Er Ke Za Zhi* 2008 Oct; 10\(5\):575-8 \[Article in Chinese\].](#)
68. [Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, et al \(2012\). Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. *Pediatr Nephrol* 2012 Mar; 27\(3\):389-96.](#)